MP
EW icon

Manifold Partners’s Edwards Lifesciences EW Stock Holding History

Manifold Partners’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-22,809
Closed -$758K – 27
2016
Q2 		$758K Sell
22,809
-4,386
-16% -$150K 0.6% 19
2016
Q1 		$800K Buy
+27,195
New +$750K 0.72% 22

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Manifold Partners's EW Position: Q3 2016 in Review

Manifold Partners sold out of Edwards Lifesciences (EW) in Q3 2016, closing a stake of 22,809 shares — an estimated $758K sold.

Manifold Partners first reported a position in EW in Q1 2016 and held it in 2 quarters. The position peaked at $800K in Q1 2016. 695 funds tracked by Wall St. Rank hold EW as of Q3 2016.

  • Manifold Partners reported no remaining Edwards Lifesciences position as of Q3 2016 after selling out during the quarter.
  • Manifold Partners sold 22,809 Edwards Lifesciences shares in Q3 2016, an estimated $758K.
  • Manifold Partners first reported a position in Edwards Lifesciences in Q1 2016 and held it in 2 quarters.
  • Manifold Partners's Edwards Lifesciences position peaked at $800K in Q1 2016.
  • 695 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2016.

Based on Manifold Partners's 13F filing for Q3 2016, filed 8 Nov 2016.